Market Performance and Corporate Developments – Caesars Entertainment (CZR)
Caesars Entertainment (CZR) closed the trading session of Friday, 23 November 2026, at USD 29.07, reflecting an increase of 0.59 % compared with the previous 24‑hour period. The stock was last quoted at 02:55 PM Central Europe time.
Trading Metrics
| Metric | Value |
|---|---|
| Current price | USD 29.07 |
| 24‑hour volume | USD 228.1 million |
| Market cap | USD 5.9 billion |
| Shares outstanding | 203.8 million |
| 52‑week high | USD 30.88 (11 March 2026) |
| 52‑week low | USD 17.86 (17 February 2026) |
| 200‑day simple moving average | USD 27.52 |
| 24‑hour change | +0.59 % |
| Month‑to‑month change | –1.82 % |
The recent price movement places the share above its 200‑day simple moving average, suggesting a short‑term bullish bias. However, the month‑to‑month decline of 1.82 % indicates modest weakness over the longer horizon.
Shareholder Structure Update
Caesars Entertainment Inc. has announced a change in its major shareholders. CZR Resources Ltd increased its stake through a takeover offer. The resulting shift in voting power has elevated the influence of CZR Resources Ltd, Yandal Investments, and Motwil Pty Ltd, which now hold a substantial proportion of the company’s ordinary shares.
In a separate governance action, the board appointed Mr. James Nicholls as the independent chair. Mr. Nicholls will preside over the upcoming shareholder meeting and will resign from the board thereafter. These changes do not have an immediate impact on the company’s financial performance, as disclosed.
Comparison with Peer Performance
The following table summarizes the 24‑hour performance of selected peer stocks:
| Stock | 24‑hour change | Current price (USD) | Market cap (USD) | P/E Ratio |
|---|---|---|---|---|
| Molson Coors Beverage (TAP) | +5.57 % | 41.67 | 7 billion | – |
| Andersen (ANDG) | +0.45 % | 63.54 | 6.9 billion | 34.38 |
| Epam (EPAM) | +3.49 % | 138.67 | 6.9 billion | 18.15 |
| Amneal (AMRX) | 0 % | 20.48 | 7 billion | 41.93 |
| Navan (NAVN) | +1.29 % | 26.03 | 6.9 billion | – |
Amneal (AMRX) continues strategic discussions with a Swedish developer regarding its ICOres® and ICOpre® generics platforms. Negotiations appear to progress positively, with potential revenue generation once the products reach market launch. The company is also engaged with several potential licensees for the ICOpre® platform and awaits a decision from the Gates Foundation regarding funding for the oxytocin formulation in its ICOone® product. Amneal’s collaborations with Aeriant and Lonza aim to broaden its development pipeline beyond respiratory indications.
Company Overview
Caesars Entertainment, Inc. operates a chain of resorts and casinos across the United States. The company offers gaming services—including casino, poker, and roulette—as well as food and beverage services.
